Method for synthesizing (R)-3-aminobutan-1-ol

Engineered aminotransaminases with specific mutations enhance the synthesis of (R)-3-aminobutan-1-ol, addressing inefficiencies and costs in dolutegravir production by improving enzymatic activity and thermostability, thereby reducing production costs and reaction times.

JP2024542776APending Publication Date: 2024-11-15VIIV HEALTHCARE CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532972
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-07
Filing Date
2022-11-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The synthesis of (R)-3-aminobutan-1-ol (RABO), a key intermediate in the production of dolutegravir, is inefficient and costly due to the high price of RABO and the complexity of purifying small molecule chiral alcohols with low boiling points.

Method used

A method involving the use of engineered aminotransaminases with specific mutations, such as those similar to SEQ ID NO: 4, to catalyze the reaction of 4-hydroxy-2-butanone with an amine donor, enhancing enzymatic activity and thermostability, thereby improving the production efficiency and reducing costs.

Benefits of technology

The engineered aminotransaminases exhibit increased activity and thermostability, leading to reduced reaction times, higher yields, and lower production costs for RABO, thus making antiretroviral therapy more accessible.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542776000001
    Figure 2024542776000001
  • Figure 2024542776000002
    Figure 2024542776000002
  • Figure 2024542776000003
    Figure 2024542776000003
Patent Text Reader

Abstract

The present invention relates to aminotransaminases useful in the synthesis of (R)-3-aminobutan-1-ol (RABO). The present invention also provides methods for the preparation of (R)-3-aminobutan-1-ol (RABO) using the disclosed aminotransaminases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to methods for the synthesis of (R)-3-aminobutan-1-ol (RABO) and polypeptides having aminotransaminase activity. [Background technology]

[0002] (4R,12aS)-9-{[(2,4-difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-7-olate, known as dolutegravir (DTG), is an integrase inhibitor (INSTI) used in the form of its sodium salt in combination with other drugs to treat HIV. See U.S. Patent No. 8,129,385.

[0003] DTG contains an S-hemiaminal chiral center that is important for protein binding and potency against common HIV mutants. According to at least one method of making DTG, the preferred stereochemistry of DTG is obtained by using an isomeric (R)-3-aminobutan-1-ol intermediate in the final ring-closure step (Johns et al., J. Med. Chem. 2013, 56, 5901-5916). However, (R)-3-aminobutan-1-ol (RABO) is relatively expensive and can be the major cost generator of DTG production - accounting for almost 30% of the total cost. The synthesis of small molecule chiral alcohols is a challenge for many reasons, including purification complications due to low boiling points (Medicines for All Initiative, Process Development Report, Synthesis of (R)-3-aminobutan-1-ol, November 8, 2019).

[0004] Transaminases or "aminotransaminases" are polypeptides having the enzymatic ability to transfer an amino group (-NH2) from a primary amine of an amine donor compound to a carbonyl group (C=O) of an amine acceptor compound. Aminotransaminase reactions can be used in methods for producing dolutegravir, and more particularly, RABO intermediates. See WO2018 / 020380. However, current versions of these aminotransaminase reactions still result in inefficient RABO production.

[0005] Thus, there is a need to identify methods for synthesizing RABO and aminotransaminases useful in the synthesis of RABO that will improve production efficiency and ultimately reduce the overall production costs of certain antiretroviral therapies directed at HIV. Summary of the Invention

[0006] According to a first aspect of the present invention, there is provided a compound of formula (I):

[0007] [ka] The method includes reacting 4-hydroxy-2-butanone with an amine donor in the presence of an aminotransaminase, the aminotransaminase comprising an amino acid sequence at least 80% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, and X223P.

[0008] According to a second aspect of the present invention there is provided an aminotransaminase comprising an amino acid sequence which is at least 80% identical to SEQ ID NO:4, wherein the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P.

[0009] According to a third aspect of the present invention there is provided an aminotransaminase comprising the amino acid sequence of SEQ ID NO:2.

[0010] According to a further aspect of the present invention there is provided an aminotransaminase consisting of the amino acid sequence of SEQ ID NO:2.

[0011] According to a further aspect of the invention there is provided a polynucleotide encoding the aminotransaminase of the invention.

[0012] According to a final aspect of the present invention, a compound of structural formula (I):

[0013] [ka] The present invention also provides the use of an aminotransaminase of the present invention for the manufacture of a compound of the formula:

[0014] The present invention is advantageous in several ways: in particular, the method of making RABO using the disclosed aminotransaminases with improved properties, such as increased activity and thermostability, can reduce reaction time, improve yield / conversion and / or stereochemical selectivity, reduce production costs, and increase convenience for people in need of antiretroviral therapy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] definition As used herein, the terms "protein," "polypeptide," and "peptide" are used interchangeably herein to refer to a polymer of at least two amino acids covalently linked by amide bonds, regardless of length or post-translational modification (e.g., glycosylation, phosphorylation, lipidation, myristylation, ubiquitination, etc.). D- and L-amino acids and mixtures of D- and L-amino acids are included within the scope of this definition.

[0016] As used herein, the terms "aminotransferase," "transaminase," and "aminotransaminase" are used interchangeably and refer to a polypeptide having the enzymatic capability of transferring an amino group (-NH), an electron pair, and a proton from a primary amine of an amine donor compound to a carbonyl group (C=O) of an amine acceptor compound, thereby converting the amine donor compound to the corresponding carbonyl compound and converting the carbonyl acceptor compound to the corresponding primary amine compound (see, e.g., Scheme 1).

[0017] [ka]

[0018] Aminotransaminases, as used herein, include naturally occurring (wild-type) aminotransaminases as well as non-naturally occurring engineered polypeptides produced by human manipulation.

[0019] The phrase "residue difference" or "amino acid difference" refers to a change in a residue at a specified position of a polypeptide sequence compared to a reference sequence. The position of a polypeptide sequence where a particular amino acid or amino acid change is present may also be described herein as "Xn" or "position n", where n refers to the residue position relative to the reference sequence. For example, a residue difference at position X8 where the reference sequence has a serine refers to a change of the residue at position X8 to any residue other than serine. As disclosed herein, the aminotransferases of the invention can contain one or more residue differences relative to the reference sequence, with multiple residue differences typically being indicated by a listing of the specified positions at which the change is made relative to the reference sequence. A particular substitution mutation, which is the replacement of a particular residue in a reference sequence with a different residue designated, may be represented by the conventional notation "X(number)Y", where X is the single letter identifier of the residue in the reference sequence, "number" is the residue position in the reference sequence, and Y is the single letter identifier of the residue replacement in the engineered sequence. Thus, for example, "the mutation X5Q relative to SEQ ID NO:4" means that the fifth amino acid from the N-terminus of SEQ ID NO:4 has been changed to Q.

[0020] As used herein, the terms "amine donor" or "amino donor" are used interchangeably to refer to a compound containing an amino group that can donate an amino group to an acceptor carbonyl compound (i.e., an amino group acceptor), thereby resulting in a carbonyl by-product. In one embodiment, the amine donor used in the present invention has the general structural formula:

[0021] [ka] In the formula, R 1 and R 2 R, when each is independently selected, is an alkyl, alkylaryl, or aryl group that is unsubstituted or substituted with one or more enzymatically non-inhibitory groups (see Scheme 1(A)). 1 is R in structure or chirality 2Exemplary amino group donors include chiral and achiral amino acids and chiral and achiral amines.

[0022] As used herein, the term "carbonyl by-product" refers to a carbonyl compound formed from an amino donor when an amino group on the amino donor is transferred to an amino acceptor in a transamination reaction. Carbonyl by-products have the general structural formula:

[0023] [ka] In the formula, R 1 and R 2 is defined above for the amino group donor (see Scheme 1(C)).

[0024] As used herein, the terms "amino acceptor," "amine acceptor," "keto substrate," "substrate," or "substrate compound" are used interchangeably to refer to a carbonyl group containing compound that accepts an amino group from an amino group donor in a reaction mediated by an aminotransaminase (see Scheme 1(B)).

[0025] As used herein, the term "cofactor" refers to a non-protein compound that functions in combination with an enzyme in catalyzing a reaction.As used herein, "cofactor" is intended to include the compounds PLP, PN, PL, PM, PNP and PMP of the vitamin B6 family, which are sometimes called coenzymes.

[0026] As used herein, the terms "pyridoxal-phosphate", "PLP", "pyridoxal-5'-phosphate", "PYP" and "P5P" are used interchangeably herein to refer to compounds that act as cofactors in aminotransaminase reactions. In some embodiments, pyridoxal phosphate is defined by the structure 1-(4'-formyl-3'-hydroxy-2'-methyl5'-pyridyl)methoxyphosphonic acid, CAS number [54-47 R2 7]. Pyridoxal-5'-phosphate can be produced in vivo by phosphorylation and oxidation of pyridoxal (also known as vitamin B). In a transamination reaction using an aminotransaminase enzyme, the amino group of the amino donor is transferred to a cofactor to generate a keto byproduct, while pyridoxal-5'-phosphate is converted to pyridoxamine phosphate. Pyridoxal-5'-phosphate is regenerated by reaction with a different keto compound (amino acceptor). The transfer of the amino group from pyridoxamine phosphate to the amino acceptor produces an amine and regenerates the cofactor. In some embodiments, pyridoxal-5' phosphate can be replaced by other members of the vitamin B6 family, including pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM) and their phosphorylated counterparts; pyridoxine phosphate (PNP) and pyridoxamine phosphate (PMP).

[0027] As used herein, the term "enzyme" refers to a class of proteins that function as biological catalysts.

[0028] As used herein, the term "biological catalyst" refers to a linear polypeptide that facilitates a chemical reaction or transformation of organic compounds.

[0029] As used herein, "coding sequence" refers to a portion of a nucleic acid (eg, a gene) that codes for the amino acid sequence of a protein.

[0030] As used herein, "naturally occurring" or "wild type" refers to a form found in nature. For example, a naturally occurring or wild type polypeptide or polynucleotide sequence is a sequence present in an organism that can be isolated from a source in nature and has not been intentionally modified by human manipulation.

[0031] As used herein, for example, when used with reference to a cell, nucleic acid, or polypeptide, "recombinant" or "engineered" or "non-naturally occurring" refers to a material, or a material that corresponds to a natural or native form of that material that has been modified in a manner that would not otherwise occur in nature, or a material that is identical thereto but produced or derived from synthetic material and / or by manipulation using recombinant techniques. Non-limiting examples include, among others, recombinant cells that express genes not found within the native (non-recombinant) form of the cell, or that express native genes that are otherwise expressed at different levels.

[0032] "Percent identity" or "% identity" between a query nucleic acid sequence and a subject nucleic acid sequence is an "identity" value expressed as a percentage, calculated using an appropriate algorithm (e.g., BLASTN, FASTA, Needleman-Wunsch, Smith-Waterman, LALIGN, or GenePAST / KERR) or software (e.g., DNASTAR Lasergene or GenePAST / KERR) over the entire length of the query sequence after performing a pairwise global sequence alignment using an appropriate algorithm (e.g., Needleman-Wunsch or GenePAST / KERR) or software (e.g., DNASTAR Lasergene, GenomeQuest, EMBOSS needle, or EMBOSS infoalign). Importantly, the query nucleic acid sequence may be described by a nucleic acid sequence disclosed herein, particularly in one or more of claims.

[0033] "Percent identity" or "% identity" between a query amino acid sequence and a subject amino acid sequence is an "identity" value expressed as a percentage, calculated using an appropriate algorithm (e.g., BLASTP, FASTA, Needleman-Wunsch, Smith-Waterman, LALIGN, or GenePAST / KERR) or software (e.g., DNASTAR Lasergene or GenePAST / KERR) over the entire length of the query sequence after performing a pairwise global sequence alignment using an appropriate algorithm (e.g., Needleman-Wunsch or GenePAST / KERR) or software (e.g., DNASTAR Lasergene, GenomeQuest, EMBOSS needle, or EMBOSS infoalign). Importantly, the query amino acid sequence may be described by the amino acid sequence disclosed herein, particularly in one or more of the claims.

[0034] The query sequence may be 100% identical to the subject sequence, or may contain up to a certain integer number of amino acid changes compared to the subject sequence, so that the identity % is less than 100%. For example, the query sequence is at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical to the subject sequence. Such changes include deletion, substitution (including conservative and non-conservative substitution), or insertion of at least one amino acid, where the changes may occur at the amino-terminal or carboxy-terminal positions of the query sequence, or anywhere between these terminal positions, and may occur individually among the amino acids in the query sequence, or in one or more consecutive groups within the query sequence.

[0035] As used herein, "reference sequence" refers to a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset of a larger sequence, such as a segment of a full-length gene or polypeptide sequence. In general, a reference sequence is at least 20 nucleotides or amino acid residues long, at least 25 residues long, at least 50 residues long, or the full length of a nucleic acid or polypeptide. Since two polynucleotides or polypeptides can each (1) contain sequences (i.e., a portion of a complete sequence) that are similar between the two sequences, and (2) further contain sequences that differ between the two sequences, sequence comparison between two (or more) polynucleotides or polypeptides is usually performed by comparing the sequences of the two polynucleotides or polypeptides over a "comparison window" to identify and compare local regions of sequence similarity. In some embodiments, a "reference sequence" can be based on a primary amino acid sequence, where the reference sequence is a sequence that can have one or more changes in the primary sequence.

[0036] As used herein, "improved enzymatic properties" refers to an aminotransaminase polypeptide that exhibits an improvement in any enzymatic property compared to a reference aminotransaminase, such as a wild-type aminotransaminase enzyme or another improved engineered aminotransaminase. The enzymatic properties for which improvement is desired include, but are not limited to, enzyme activity (which may be expressed as a percentage of conversion of substrate), thermostability, solvent stability, pH activity profile, cofactor requirements, refractoriness to inhibitors (e.g., substrate or product inhibition), stereospecificity and stereoselectivity (including enantioselectivity).

[0037] As used herein, "improved or higher enzyme activity" refers to improved activity of an engineered aminotransaminase polypeptide, which may be expressed in terms of improved specific activity (e.g., product produced / time / weight protein) or improved percent conversion of substrate to product (e.g., percent conversion of amount of substrate to product within a specified period of time using a specified amount of aminotransaminase) compared to a reference aminotransaminase enzyme. Exemplary methods for determining enzyme activity are provided in the Examples. Any property associated with enzyme activity may be affected, including classical enzyme properties of Km, Vmax, or kcar, and these changes may result in improved enzyme activity. The improvement in enzyme activity can be from about 1.1-fold improvement (FIOP) over the parent of the enzyme activity of the corresponding wild-type aminotransaminase enzyme to as much as 2 FIOPs, 5 FIOPs, 10 FIOPs, 20 FIOPs, 25 FIOPs, 50 FIOPs, 75 FIOPs, 100 FIOPs or more enzyme activity than the naturally occurring aminotransaminase or another engineered aminotransaminase from which the aminotransaminase polypeptide was derived. The aminotransaminase activity can be measured by any one of the standard assays, for example, by monitoring the change in the spectrophotometric properties of the reactants or products. In some embodiments, the amount of product produced can be measured by known assays using o-phthaldialdehyde (OPA) derivatization followed by high performance liquid chromatography (HPLC) separation combined with UV absorbance or fluorescence detection. The comparison of enzyme activity is made using a defined preparation of the enzyme, a defined assay under set conditions, and one or more defined substrates, as described in more detail herein. Generally, when lysates are compared, the use of the same expression system and the same host cells can be determined to minimize variation in the number of cells and the amount of protein assayed, as well as the amount of enzyme produced by the host cells and present in the lysate.

[0038] The abbreviations used for the genetically encoded amino acids are conventional and are as follows:

[0039] [Table 1]

[0040] Description of the invention The present disclosure provides aminotransaminases having aminotransaminase activity, useful in some embodiments for the selective transamination of an amino acceptor substrate compound to produce the pharmaceutical ingredient (R)-3-aminobutan-1-ol (RABO). In certain embodiments, the aminotransaminase has aminotransaminase activity capable of converting the substrate compound to formula (I). In further embodiments, the amino acceptor substrate compound is 4-hydroxy-2-butanone. Additionally, the present disclosure provides nucleic acid sequences encoding the aminotransaminases of the present invention.

[0041] The aminotransaminases of the disclosure are non-naturally occurring aminotransaminases that have been engineered to have improved enzymatic properties, such as reaction yield and / or thermal stability, compared to the reference aminotransaminase polypeptide of SEQ ID NO:4.

[0042] According to a first aspect, the present invention provides a compound of structural formula (I):

[0043] [ka] The present invention provides a method for preparing a compound of formula (I) comprising reacting 4-hydroxy-2-butanone with an amine donor in the presence of an aminotransaminase, the aminotransaminase comprising an amino acid sequence at least 80% identical to SEQ ID NO:4, and the aminotransaminase comprising the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, and X223P.

[0044] According to a second aspect, the present invention provides an aminotransaminase comprising an amino acid sequence which is at least 80% identical to SEQ ID NO:4, wherein the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P.

[0045] In one embodiment, the aminotransaminase of the invention or used in the method of the invention additionally comprises the mutation X165N relative to SEQ ID NO: 4, i.e. the aminotransaminase comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 4 and comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P and X165N.

[0046] In another embodiment, the aminotransaminase of the invention or used in the method of the invention additionally comprises the mutation X215A relative to SEQ ID NO:4, i.e. the aminotransaminase comprises an amino acid sequence which is at least 80% identical to SEQ ID NO:4 and comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P and X215N.

[0047] In one embodiment, the aminotransaminase of the invention or used in the method of the invention comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P, X165N and X215A.

[0048] In one embodiment, the aminotransaminase of the invention or used in the methods of the invention comprises an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P.

[0049] In one embodiment, the aminotransaminase of the invention or used in the methods of the invention comprises an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P and X165N.

[0050] In one embodiment, the aminotransaminase of the invention or used in the methods of the invention comprises an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P and X215A.

[0051] In one embodiment, the aminotransaminase of the invention or used in the methods of the invention comprises an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P, X165N and X215A.

[0052] In one embodiment, the amino transaminase of the invention or for use in the method of the invention comprises the amino acid sequence of SEQ ID NO: 2. In another embodiment, the amino transaminase of the invention or for use in the method of the invention consists of the amino acid sequence of SEQ ID NO: 2.

[0053] In one embodiment, the aminotransaminase of the invention or used in the method of the invention provides an amine donor. In one embodiment, the amine donor is isopropylamine of formula C3H9N. In one embodiment, the amine donor is methylbenzylamine of formula C7H9N. In an embodiment, the amine donor is R-methylbenzylamine of formula C6H5CH(NH2)CH3.

[0054] In one embodiment, the aminotransaminase of the present invention or used in the method of the present invention requires cofactor.In one embodiment, the cofactor comprises a vitamin B6 family compound.In one embodiment, the vitamin B6 family compound is selected from the group consisting of PLP, PN, PL, PM, PYP, P5P, PNP and PMP.In one embodiment, the cofactor comprises PLP.

[0055] In one embodiment, the present invention provides a method as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention, The aminotransaminase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:4, and the aminotransaminase comprises the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P, and the aminotransaminase exhibits higher activity than the enzyme of SEQ ID NO:4.

[0056] In one embodiment, the aminotransaminase of the present invention is 4-Hydroxy-2-butanone exhibits higher activity when measured using about 70 g / L, about 80 g / L, about 90 g / L or about 100 g / L, about 1.5 M, about 1.75 M, about 2.0 M, about 2.25 M or about 2.5 M isopropylamine or about 1.0 M, about 1.25 or about 1.5 M R-methylbenzylamine at about pH 8, about pH 9, about pH 10 or about pH 11, at about 30° C., about 35° C., about 37° C., about 40° C. to about 45° C., for about 20 hours, about 24 hours, about 28 hours, about 32 hours, about 36 hours, about 40 hours, about 44 hours or about 48 hours. In one embodiment, the aminotransaminase of the invention exhibits higher activity towards SEQ ID NO: 4 when measured using 100 g / L 4-hydroxy-2-butanone, 1.4 M R-methylbenzylamine at about pH 8.0, about pH 8.1, about pH 8.2, about pH 8.3, about pH 8.4 or pH 8.5 at about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C. or about 45° C. for about 20 hours. In one embodiment, the aminotransaminase of the invention exhibits higher activity when measured using 100 g / L 4-hydroxy-2-butanone, 1.4 M R-methylbenzylamine at about pH 8.5, about 40° C. for about 20 hours.

[0057] In certain embodiments, the aminotransaminase of the invention or used in the methods of the invention has a transaminase activity to convert a substrate compound to formula (I) that is improved by at least about 300, 310, 320, 330, 340, 350, 400, 450, 500, 510, 520, 530, 540, 1000 FIOPs or more under suitable reaction conditions (e.g., when measured over 24 hours at about pH 8.5, 40°C-45°C using 100 g / L 4-hydroxy-2-butanone, 1.4 M R-methylbenzylamine) relative to the activity of a reference polypeptide of SEQ ID NO: 4. In certain embodiments, the aminotransaminase of the invention has a transaminase activity to convert a substrate compound to formula (I) that is improved by at least about 300 FIOPs-500 FIOPs relative to the activity of a reference polypeptide of SEQ ID NO: 4. In certain embodiments, the aminotransaminase has transaminase activity to convert a substrate compound to formula (I), but with an activity that is at least about 350 FIOPs to 550 FIOPs improved over the activity of a reference polypeptide of SEQ ID NO: 4. In certain embodiments, the aminotransaminase has transaminase activity to convert a substrate compound to formula (I), but with an activity that is at least about 360 FIOPs to about 540 FIOPs improved.

[0058] Thus, in one embodiment, the present invention provides a method as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention, wherein the aminotransaminase comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 4, and wherein the aminotransaminase comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P, and wherein the aminotransaminase exhibits improved activity compared to the enzyme of SEQ ID NO: 4 as measured by a FIOP of more than 300.

[0059] In one embodiment, the invention provides a method as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention, wherein the aminotransaminase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 4, and wherein the aminotransaminase comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L, X223P, X165N and X215A, and wherein the aminotransaminase exhibits improved activity compared to the enzyme of SEQ ID NO: 4 as measured by a FIOP of more than 500. In certain embodiments, the aminotransaminases of the invention have transaminase activity capable of converting a substrate compound to formula (I) as described in Example 4, but with a percent conversion of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least 96%, at least 97%, at least about 98%, or at least about 99% in about 48 hours, about 36 hours, about 24 hours, about 20 hours of reaction time, or even shorter lengths of time, under suitable reaction conditions (e.g., when measured using 100 g / L 4-hydroxy-2-butanone, 1.4 M R-methylbenzylamine, at about pH 8.5, at 40° C.-45° C., over a period of 20 hours). In certain embodiments, the aminotransaminases of the present invention are capable of converting the substrate compound to formula (I) with a percent conversion of at least about 90% within a reaction time of about 20-48 hours, e.g., about 20 hours, about 24 hours, about 30 hours, about 35 hours, about 40 hours, about 45 hours, or about 48 hours. In one embodiment, the percent conversion is at least about 95% within a reaction time of about 20-48 hours, e.g., about 20 hours, about 24 hours, about 30 hours, about 35 hours, about 40 hours, about 45 hours, or about 48 hours.In one embodiment, the aminotransaminase has a transaminase activity capable of converting a substrate compound of formula (I) to 4-hydroxy-2-butanone at about 30° C., about 31° C., about 32° C., about 70 g / L, about 80 g / L, about 90 g / L, or about 100 g / L, about 1.5 M, about 1.75 M, about 2.0 M, about 2.25 M, or about 2.5 M isopropylamine, or about 1.0 M, about 1.25 M, or about 1.5 M R-methylbenzylamine, at about pH 8, about pH 9, about pH 10, or about pH 11. In the range of at least 90%, 95%, 96%, 97%, 98%, 99% or more enantiomeric excess under suitable reaction conditions at about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C or about 45°C for about 20 hours, about 21 hours, about 22 hours, about 23 hours or about 24 hours. In one embodiment, the aminotransaminase has a transaminase activity capable of converting a substrate compound to formula (I) in a range of at least 90%, 95%, 96%, 97%, 98%, 99% or more enantiomeric excess under suitable reaction conditions at about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C. or about 45° C. for about 20 hours, about 21 hours, about 22 hours, about 23 hours or about 24 hours, when measured using 100 g / L 4-hydroxy-2-butanone, 1.4 M R-methylbenzylamine at about pH 8.5.

[0060] In one embodiment, the invention provides a method as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention, wherein the aminotransaminase comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 4, and wherein the aminotransaminase comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P, and wherein the aminotransaminase exhibits greater thermostability than the enzyme of SEQ ID NO: 4. In one embodiment, the aminotransaminase of the invention exhibits improved activity at 50° C. than the enzyme of SEQ ID NO: 4.

[0061] The present invention also provides a composition comprising an aminotransaminase as defined in the second aspect of the invention.

[0062] In some embodiments, the aminotransaminase is an immobilized aminotransaminase. In some embodiments, the immobilized aminotransaminase is linked to a protein-immobilized bead.

[0063] The method of the present invention comprises reacting butanone with an amine donor. Butanone, also known as methyl ethyl ketone, is an organic compound of formula CH3C(O)CH2CH3.

[0064] In an embodiment, the present invention provides a polynucleotide encoding an aminotransaminase as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention. In an embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1. In an embodiment, the polynucleotide consists of the nucleotide sequence of SEQ ID NO: 1.

[0065] In certain embodiments, the present invention provides a DNA sequence of a polynucleotide encoding an aminotransaminase as defined in the first aspect of the invention or an aminotransaminase as defined in the second aspect of the invention. If the sequence of the engineered polypeptide is known, the polynucleotide encoding the enzyme can be prepared by standard solid-phase methods according to known synthesis methods. In some embodiments, fragments of up to about 100 bases can be synthesized separately and then linked (e.g., by enzymatic or chemical ligation methods, or by polymerase-mediated methods) to form any contiguous sequence desired. For example, the polynucleotides and oligonucleotides of the present invention can be prepared by chemical synthesis, for example using the classical phosphoramidite method described in Beaucage et al., 1981, Tet Lett 22:1859-69 or the method described in Matthes et al., 1984, EMBO J.3:801-05, as is usually performed in automated synthesis methods. According to the phosphoramidite method, oligonucleotides are synthesized, for example, in an automatic DNA synthesizer, purified, annealed, ligated and cloned into an appropriate vector. Additionally, essentially any nucleic acid can be obtained from any of a variety of commercial sources, including The Great American Gene Company, Ramona, Calif., ExpressGen Inc, Chicago, Ill., Operon Technologies Inc, Alameda, Calif., and many others.

[0066] The following non-limiting examples illustrate the invention. EXAMPLES

[0067] [Example 1] Production of Aminotransferase Powder – Shake Flask Procedure A single microbial colony of Escherichia coli (E. coli) containing a plasmid encoding the aminotransferase of interest was inoculated into 50 mL of Luria Bertoni broth containing 30 μg / mL chloramphenicol and 1% glucose. The cells were grown overnight (at least 16 hours) in an incubator at 30°C with shaking at 250 rpm. The culture was diluted into 1000 mL of 2xYT containing 30 μg / mL chloramphenicol (supplemented with 0.1 mM pyridoxine) to give an OD600 of approximately 0.2 and grown at 30°C with shaking at 250 rpm. Expression of the aminotransferase gene was induced by the addition of isopropyl β D-thiogalactoside (IPTG) to a final concentration of 1 mM when the OD600 of the culture was 0.6-0.8. Incubation was then continued overnight (at least 16 hours). Cells were harvested by centrifugation (3738 RCF, 20 min, 4°C) and the supernatant was discarded. The pellet was frozen at -80°C for 2 hours. The pellet was then thawed and resuspended in 4 mL of 40 mM potassium phosphate buffer (pH 7.4) per gram of final pellet mass (e.g., 10 g of frozen pellet was suspended in 40 mL of buffer). After resuspension, cells were filtered through a 200 um mesh and then passed twice through a microfluidizer at 12000 psig. Cell debris was removed by centrifugation (15,777 RCF, 40 min, 4°C). The cleared lysate supernatant was collected, pooled, and lyophilized to obtain a dry powder of crude aminotransferase enzyme.

[0068] [Example 2] Aminotransferase powder production-fermentation procedure An aliquot of frozen working stock (E. coli containing a plasmid with the aminotransferase gene of interest) was removed from the freezer and thawed at room temperature. 300 μL of this working stock was inoculated into a primary seed stage of 250 ml of M9YE broth (1.0 g / L ammonium chloride, 0.5 g / L sodium chloride, 6.0 g / L disodium monohydrogen phosphate, 3.0 g / L potassium dihydrogen phosphate, 2.0 g / L Procelys Springer 0251 yeast extract, 1 L / L deionized water) containing 30 μg / ml chloramphenicol and 1% glucose in a 1 L flask and grown at 37 °C with shaking at 200 rpm. When the OD600 of the culture was 0.5-1.0, the flask was removed from the incubator and used immediately to inoculate the secondary seed stage.

[0069] The secondary seed stage was carried out in a bench-scale 5 L fermentor using 4 L of growth medium (0.88 g / L ammonium sulfate, 0.98 g / L trisodium citrate dihydrate; 12.5 g / L dipotassium hydrogen phosphate, 6.25 g / L potassium dihydrogen phosphate, 3.3 g / L Procelys Springer 0251 yeast extract, 0.083 g / L ferric ammonium citrate, 0.5 ml / L polypropylene glycol antifoam, and 8.3 ml / L trace element solution, 1 L / L process water. The trace element solution contained 2 g / L calcium chloride dihydrate, 2.2 g / L zinc sulfate heptahydrate, 0.5 g / L manganese sulfate monohydrate, 1 g / L copper sulfate pentahydrate, 0.1 g / L ammonium molybdate tetrahydrate, and 0.02 g / L sodium tetraborate decahydrate, 1 L / L deionized water). The growth medium was sterilized at 121°C for 40 min. After sterilization, 40 ml / L of feedstock solution was added (feedstock solution contained 12 g / L ammonium sulfate, 5.1 g / L magnesium sulfate heptahydrate, 500 g / L dextrose monohydrate, 1 L / L process water, and sterilized at 121°C for 30 min). The fermenter was inoculated with 2 ml of primary seed at OD600 0.5-1.0, supplemented with 30 μg / ml chloramphenicol, and incubated at 37°C, 300 rpm, and 0.5 vvm aeration. When the OD600 of the culture was 0.5-1.0, the secondary seed was immediately transferred to the final stage of fermentation.

[0070] Final stage fermentations were carried out at bench scale in 10 L fermenters using 6 L of growth medium (ammonium sulfate 0.88 g / L, trisodium citrate dihydrate 0.98 g / L; dipotassium hydrogen phosphate 12.5 g / L, potassium dihydrogen phosphate 6.25 g / L, Procelys Springer 0251 yeast extract 3.3 g / L, ammonium ferric citrate 0.083 g / L, polypropylene glycol antifoam 0.5 ml / L, and trace element solution 8.3 ml / L, process water 1 L / L. The trace element solution contained calcium chloride dihydrate 2 g / L, zinc sulfate heptahydrate 2.2 g / L, manganese sulfate monohydrate 0.5 g / L, copper sulfate pentahydrate 1 g / L, ammonium molybdate tetrahydrate 0.1 g / L, and sodium tetraborate decahydrate 0.02 g / L, deionized water 1 L / L). The growth medium was sterilized for 40 minutes at 121° C. After sterilization, the growth medium was supplemented with 0.035 g / L pyridoxine hydrochloride and 40 ml / L feedstock solution (feedstock solution contained 12 g / L ammonium sulfate, 5.1 g / L magnesium sulfate heptahydrate, 500 g / L dextrose monohydrate, 1 L / L process water and was sterilized for 30 minutes at 121° C.).

[0071] The fermenter was inoculated with 500 ml of secondary seed at OD600 0.5-1.0 and incubated at 37°C and 0.5 vvm aeration. Dissolved oxygen was controlled at 30% by variable speed agitation and pH was maintained at p7.0 by addition of 17.5% v / v ammonium hydroxide solution. Growth of the culture was maintained by addition of feedstock solution (12 g / L ammonium sulfate, 5.1 g / L magnesium sulfate heptahydrate, 500 g / L dextrose monohydrate, 1 L / L process water, sterilized at 121°C for 30 min). After the culture reached an OD600 of 80+ / -10, the temperature was reduced to 30°C and isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 1 mM. Fermentation was continued for a further 18 hours. At harvest, the culture was cooled to 8°C. Cells were harvested by centrifugation at 5000G for 40 minutes in a Sorvall RC12BP centrifuge at 4° C. The harvested cell pellet was then frozen at −80° C. and stored until downstream processing and harvesting.

[0072] [Example 3] Production of aminotransferase catalyst - immobilization procedure The protein content of the lyophilized crude aminotransferase was quantified by Bradford assay. The addition of 15 g of crude enzyme was calculated to a final protein concentration of 27 mg protein per gram of resin (500-650 mg) and weighed into a 50 mL Erlenmeyer flask. 15 mL of resuspension buffer (KH2PO4 1.14 g / L, K2HPO4 5.47 g / L and PLP 1.6 g / L) was added and the protein suspension was gently mixed by inversion.

[0073] Purolite epoxy methacrylate resin (ECR8206F / 5730) was weighed into a glass 125 mL Erlenmeyer flask. A 3M high salt immobilization buffer was prepared so that the final concentration during immobilization was 1.8M. 121.09 g K2HPO4 and 25.91 g KH2PO4 were added to 250 mL water and dissolved by heating. The solution was allowed to cool and 22.5 mL was added to 15 g of resin in a glass 125 mL Erlenmeyer flask. The protein solution was then added to the resin and buffer, covered with parafilm, and incubated at 25°C, 115 rpm over the weekend.

[0074] The resin was decanted onto a 200 um square mesh and washed through a Buchner funnel with wash buffer (K2HPO4 1.25 g / L and KH2PO4 0.35 g / L) until the filtrate was clear. The resin was blotted dry with paper towels and stored at 4°C until use.

[0075] [Example 4] A high-throughput screen for the identification of aminotransferase variants of Arthrobacter species capable of converting ketone substrates to amines. The gene encoding the aminotransferase of Arthrobacter sp. (SEQ ID NO: 4), constructed as described in Example 2, was mutagenized using the methods described below, and the population of modified DNA molecules was used to transform a suitable E. coli host strain. Antibiotic resistant transformants were selected and treated to identify those expressing an aminotransferase with improved ability to carry out the reaction (substrate compound and formula (I)) under the desired reaction conditions. Cell selection, growth, induced expression of the aminotransferase variant enzyme, and harvesting of cell pellets were as described below.

[0076] Recombinant E. coli colonies carrying genes encoding aminotransferases were picked into 96-well shallow-well microtiter plates, each containing 180 μL of LB broth, 1% glucose, and 30 μg / mL of chloramphenicol (CAM), using a Q-PIX Molecular Devices robotic colony picker (Genetix USA, Inc., Boston, MA). Cells were grown overnight at 30 °C and 85% humidity with shaking at 200 rpm. A 20 μL aliquot of this culture was then transferred to a 96 deep-well plate containing 380 μL of 2xYT broth and 30 μg / mL of CAM, supplemented with 100 μL of pyridoxine. After incubating the deep-well plate at 30 °C and 85% humidity with shaking at 250 rpm for 2–3 h, recombinant gene expression in the cultured cells was induced by the addition of IPTG to a final concentration of 1 mM. Plates were then incubated for 18 hours at 30°C and 85% humidity with shaking at 250 rpm. Cells were pelleted by centrifugation (3738RCF, 10 minutes, 4°C), resuspended in 200 μL of lysis buffer, and lysed by shaking at room temperature for 2 hours. The lysis buffer for early stage engineered aminotransferases consisted of 25 mM triethanolamine, pH 7.5, lysozyme 1 mg / mL, polymyxin B sulfate 500 μg / mL, and 1 mM pyridoxal phosphate.

[0077] Lysis buffer for late stage engineered aminotransferases consisted of 100 mM potassium phosphate, pH 8.0, lysozyme 1 mg / mL, polymyxin B sulfate 500 μg / mL, and 1 mM pyridoxal phosphate (PLP). Plates were sealed with air permeable nylon seals and then shaken vigorously for 2 hours at room temperature. Cell debris was pelleted by centrifugation (3738 RCF, 10 min, 4°C) and the cleared supernatant was either assayed directly or stored at 4°C until use.

[0078] For early stage engineered aminotransferase screening, isopropylamine was used as the amine donor. For all plates, ketone, amine donor, cosolvent and 1 mM PLP were premixed as reaction mix concentrate and diluted to final concentration by addition of lysate to initiate the reaction. Each well of a Costar deep well plate was loaded with reaction mix concentrate, followed by addition of harvested lysate supernatant using a Biomek FX robotic device (Beckman Coulter, Fullerton, CA). Plates were heat sealed with aluminum / polypropylene laminate heat seal tape at 165°C for 4 seconds and incubated at 650 rpm (INFORS Thermotron) for 20 hours. Mutant conditions are summarized below. Reactions were prepared for analysis as described in Example 5.

[0079] SEQ ID NO:4: 30% lysate, 4-hydroxy-2-butanone 77 g / L, 1.5 M isopropylamine (pH 10), 5% v / v methanol, 30°C.

[0080] SEQ ID NO:6: 30% lysate, 4-hydroxy-2-butanone 100 g / L, 2.5 M isopropylamine (pH 10), 5% v / v isopropanol, 30°C.

[0081] SEQ ID NO:8: 25% lysate, 4-hydroxy-2-butanone 130 g / L, 2.5 M isopropylamine (pH 10.75), 25% v / v DMSO, 45°C.

[0082] For screening of late stage engineered aminotransferases (e.g., SEQ ID NO: 10, 12, 2), R-methylbenzylamine (R-MBA) was used as the amine donor. In some cases, a preincubation step with acetophenone byproduct was included. For preincubation, each well of a Costar deep well plate was loaded with 18 μL of 50% acetophenone in DMSO, followed by the addition of 71.1 μL of harvested lysate supernatant using a Biomek FX robotic device (Beckman Coulter, Fullerton, CA). Plates were heat sealed with aluminum / polypropylene laminate heat seal tape at 165°C for 4 seconds and incubated at 40°C, 850 rpm (INFORS Thermotron) for 20 hours.

[0083] For all plates, ketone and amine donors were premixed as reaction mix concentrates and diluted to final concentrations by addition to preincubated lysates to initiate reactions. Each well of a Costar deep-well plate was loaded with reaction mix concentrates using a Biomek FX robotic device (Beckman Coulter, Fullerton, CA). Plates were heat sealed with aluminum / polypropylene laminate heat seal tape at 165°C for 4 seconds and incubated at 650 rpm (INFORS Thermotron) for 20 hours. Mutant conditions are summarized below. Reactions were prepared for analysis as described in Example 5.

[0084] SEQ ID NO:10: 35.5% lysate, acetophenone, then preincubated with 4-hydroxy-2-butanone 100 g / L, 1.4 M R-MBA (pH 8.5), 40°C.

[0085] SEQ ID NO:12: 35.5% lysate, acetophenone, then preincubated with 4-hydroxy-2-butanone 100 g / L, 1.4 M R-MBA (pH 8.5), 45°C.

[0086] SEQ ID NO:2: 35.5% lysate, acetophenone, then preincubated with 4-hydroxy-2-butanone 100 g / L, 1.4 M R-MBA (pH 8.5), 35-45°C.

[0087] For screening of late stage engineered aminotransferases with temperature exposure, the reactions proceeded as follows: Exposure to elevated temperatures allowed for the identification of mutations that correlated with improved stability. Ketone and amine donors were premixed as reaction mix concentrates and diluted to final concentrations by addition of lysate to initiate the reaction. Each well of a Costar deep well plate was loaded with reaction mix concentrates, followed by addition of harvested lysate supernatant using a Biomek FX robotic device (Beckman Coulter, Fullerton, CA). Plates were heat sealed with aluminum / polypropylene laminate heat seal tape at 165°C for 4 seconds and incubated at 650 rpm (INFORS Thermotron) for 20 hours. Mutant conditions are summarized below. Reactions were prepared for analysis as described in Example 5.

[0088] SEQ ID NO:12: 44.55% lysate, 4-hydroxy-2-butanone 100 g / L, 1.4M R-MBA (pH 8.5), 50° C. SEQ ID NO:12 has a FIOP of 1.428 over SEQ ID NO:10 under the test conditions provided above.

[0089] In Example 4 above, the above reaction of an aminotransferase converting a substrate compound to an amine can be shown as follows:

[0090] [ka]

[0091] [Example 5] A high-throughput analytical method for the identification of aminotransferase variants of Arthrobacter species capable of converting ketone substrates to amines. Derivatization of the amine product with Murphy's reagent: After overnight reactions, plates were removed from the incubator, seals were removed, and reactions were diluted with water. For early stage engineered aminotransferases, samples were diluted 3-fold. For late stage engineered aminotransferases, samples were diluted 10-fold (in two steps). Plates were heat sealed with aluminum / polypropylene laminate heat seal tape at 165°C for 4 seconds, shaken for 10 minutes, and then centrifuged at 3738 RCF for 10 minutes to pellet debris.

[0092] 1% Murphy's reagent (10 g / L in acetonitrile) was prepared. 30 μL of 1M NaHCO3 was transferred to a new 96-deep-well plate, followed by 20 μL of 10-fold diluted supernatant and 200 μL of 1% Murphy's reagent. The plate was sealed and incubated for 1 h at 40 °C and 850 rpm (INFORS Thermotron).

[0093] Derivatization was quenched by the addition of an equal volume of 2N HCl:acetonitrile 1:9. The plate was mixed for 5 minutes and then centrifuged at 3738 RCF for 10 minutes to pellet debris. The seal was removed and 20 μL of supernatant was transferred to 180 μL of acetonitrile in a new shallow-well polypropylene plate. The plate was resealed, mixed, and analyzed by UPLC.

[0094] UPLC method for qualitative determination of amine products after derivatization with Murphy's reagent: The enzymatic conversion of the ketone substrate of formula I (commercially available 4-hydroxy-2-butanone, CAS number 590-90-9) to the amine of formula III was determined using an Agilent 1290 UPLC equipped with an Agilent Zorbax SB-C18 RRHD column (3.0 x 50 mm, 1.8 μm) using a gradient of 0.05% trifluoroacetic acid in water (mobile phase A) and 0.05% trifluoroacetic acid in acetonitrile (mobile phase B) at a flow rate of 1.5 mL / min and a column temperature of 60 °C. The method started with a ratio of 75:25 A:B followed by a 0.2 min hold, followed by a 0.4 min gradient to 56:44 A:B, then a 0.15 min purge gradient to 0:100 A:B, a 0.15 min hold at 0:100 A:B and a 0.1 min gradient to 80:20 A:B and a final 0.25 min hold at 80:20 A:B. Compound elution was monitored at 340, with excess Murphy's Reagent eluting at 0.58 min, followed by derivatized RABO at 0.66, and excess amine donor (R-MBA) ketone eluting as a narrow peak at 0.84 min.

[0095] [Table 2]

[0096] [Table 3] JPEG2024542776000011.jpg176160 JPEG2024542776000012.jpg176160 JPEG2024542776000013.jpg177160 JPEG2024542776000014.jpg177160 JPEG2024542776000015.jpg177160

Claims

1. Formula (I) 【Chemistry 1】 1. A method for preparing a compound of the formula: reacting 4-hydroxy-2-butanone with an amine donor in the presence of an aminotransaminase; the amino acid transaminase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:4; and The aminotransaminase comprises the following mutations relative to SEQ ID NO: 4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P; method.

2. 2. The method of claim 1, wherein the aminotransaminase additionally comprises the mutation X165N relative to SEQ ID NO:

4.

3. 3. The method of claim 1 or 2, wherein the aminotransaminase additionally comprises the mutation X215A relative to SEQ ID NO:

4.

4. The method of any one of claims 1 to 3, wherein the amino transaminase comprises an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:

4.

5. The method of any one of claims 1 to 4, wherein the aminotransaminase comprises the amino acid sequence of SEQ ID NO:

2.

6. The method of claim 5, wherein the aminotransaminase consists of the amino acid sequence of SEQ ID NO:

2.

7. The method of any one of claims 1 to 6, wherein the amine donor is methylbenzylamine.

8. The method of claim 7, wherein the amine donor is R-methylbenzylamine.

9. 1. An amino acid transaminase comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:4, Including the following mutations relative to SEQ ID NO:4: X5Q, X8A, X31Q, X54C, X61I, X94I, X102K, X136W, X162G, X181W, X187I, X199I, X209L and X223P, Aminotransaminases.

10. 10. The aminotransaminase of claim 9, further comprising the following mutations relative to SEQ ID NO: 4: X165N and X215A.

11. An amino acid transaminase comprising the amino acid sequence of SEQ ID NO:

2.

12. An amino acid transaminase consisting of the amino acid sequence of SEQ ID NO:

2.

13. A polynucleotide encoding the aminotransaminase according to any one of claims 9 to 12.

14. The polynucleotide of claim 13, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:

1.

15. Formula (I): 【Chemistry 2】 For the preparation of the compound Use of an aminotransaminase according to any one of claims 9 to 12.